Nam H. Dang

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Jorge Romaguera, Luis Fayad, Maria Alma Rodriguez et al. · Journal of Clinical Oncology · 2005 · 559 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

André Goy, Anas Younes, Peter McLaughlin et al. · Journal of Clinical Oncology · 2004 · 527 citations · Full text

Medicine, Hematology, Pharmacology +15

Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects

Noriko Otsuki, Nam H. Dang, Emi Kumagai et al. · Journal of Ethnopharmacology · 2009 · 388 citations

Medicine, Pharmacology, Plant Sciences +17

Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma

Maricer P. Escalón, Nina S. Liu, Ying Yang et al. · Cancer · 2005 · 225 citations · Full text

Medicine, Oncology, Chemotherapy +12